Clinical trials: High-Risk Cancer
Refractory Plasma Cell Myeloma
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
This phase II trial studies the side-effects and anti-cancer effects of giving an autologous or syngeneic stem cell transplant followed by an allogeneic donor stem cell transplant and bortezomib.
- Trial name
- NCT00793572
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004088
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
This was an open label, multi-center protocol for U.S. patients enrolled in the study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast…
- Trial name
- EarLEE-1 (NCT03078751)
- Testing
- Ribociclib, Adjuvant endocrine therapy
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Neuroblastoma, Sarcoma
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Background: Pediatric solid tumors (Ewing's sarcoma, rhabdomyosarcoma, and neuroblastoma) are often difficult to cure with standard treatment.
- Conditions
- Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar
- Trial name
- NCT00923351
- Testing
- Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- SORAYA (NCT04296890)
- Testing
- Mirvetuximab Soravtansine
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- ImmunoGen, Inc.
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
- Conditions
- Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT04745559
- Testing
- Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
- Trial name
- OlympiA (NCT02032823)
- Testing
- Olaparib
- Where
- 698 sites in United States, Argentina and 22 more
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
Brain Tumors
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid…
- Trial name
- NCT00528437
- Testing
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- NYU Langone Health
Urinary Bladder Neoplasms
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Background: Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the immune system find and destroy cancer cells.
- Trial name
- NCT03258593
- Testing
- Durvalumab, Vicineum, Acetaminophen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Gliosarcoma
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Background: Growth of new blood vessels (angiogenesis) provides many tumors, including brain tumors, with needed nutrients and oxygen for cancer cells to survive.
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00995007
- Testing
- ZD6474 (Vandetanib), Carboplatin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)
Head And Neck Cancer, Oropharynx Cancer
OraTest in Combination With Visual Examination and Visual Examination Alone
Primary Objectives: 1. To assess the ratio in sensitivities of OraTest® in combination with visual examination versus visual examination alone in the detection of serious pathology defined as severe dysplasia, CIS, or cancer of…
- Trial name
- NCT00537199
- Testing
- Visual Examination, OraTest
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Squamous Cell Carcinoma of the Head and Neck
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
A small group of skin cancers of the head and neck, called resected cutaneous squamous carcinomas, are more aggressive than most cancers of this type, even after being treated with standard therapy.
- Trial name
- NCT03057613
- Testing
- Pembrolizumab, IMRT 60-66Gy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Case Comprehensive Cancer Center
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Background: Human papillomavirus (HPV) can cause vulvar high-grade squamous intraepithelial lesions (HSIL). Sometimes, this can become cancer. Researchers want to see if T cell therapy can treat vulvar HSIL.
- Conditions
- Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
- Trial name
- NCT03937791
- Testing
- E7 T Cell Receptor (TCR)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Barrett's Esophagus
Cryo Balloon for Residual Barrett's Esophagus
This study is being done to see if treating residual Barrett's Esophagus after previously having undergone Radiofrequency ablation or Endoscopic Mucosal resection can be eliminated with focal cryotherapy.
- Trial name
- Cryoballoon (NCT02230410)
- Testing
- CryoBalloon Focal Ablation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Leukemia
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with azacitidine to patients with MDS or AML.
- Trial name
- NCT01038635
- Testing
- 5-Azacytidine, Lenalidomide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine, may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- NCT00253435
- Testing
- Filgrastim, Carboplatin, Etoposide
- Where
- 15 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft…
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02180867
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given after combination chemotherapy with or without rituximab and stem cell transplant and to see how well it works in treating patients with…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01035463
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Nebraska
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.